La vendita allo scoperto per Allogene Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Allogene Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Allogene Therapeutics (NASDAQ:ALLO) Azioni, Report sulle vendite allo scoperto

Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics Inc

ALLON THERAPEUTICS INC by Allon Therapeutics Inc.

ALLOVIR INC

Allot Ltd

Earnings

News

ZBAO

Zhibao Technology Revises H1 EPS From $(0.01) To $(0.00), Sales $20.05M

<h3>Gainers</h3>
<ul>
<li><strong>Jiade</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares rose 10.7% to $0.83 during Friday's after-market session. The company's market cap stands at $20.2 million. </li>
<li><strong>Lobo EV Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares increased by 8.55% to $0.69. The company's market cap stands at $5.9 million. The company's, FY earnings came out 3 days ago. </li>
<li><strong>QVC Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock moved upwards by 6.59% to $0.17. The market value of their outstanding shares is at $67.7 million. </li>
<li><strong>Mingteng International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares moved upwards by 5.13% to $7.99. The company's market cap stands at $54.6 million. As per the press release, FY earnings came out 2 days ago. </li>
<li><strong>Lazydays Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock rose 4.99% to $0.21. The market value of their outstanding shares is at $23.0 million. </li>
<li><strong>Fly-E Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) stock moved upwards by 4.98% to $0.44. The company's market cap stands at $10.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Netclass Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) stock decreased by 8.6% to $15.99 during Friday's after-market session. The company's market cap stands at $285.1 million. </li>
<li><strong>Mixed Martial Arts Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 6.69% to $0.8. The company's market cap stands at $8.4 million. </li>
<li><strong>Wag Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares declined by 5.87% to $0.15. The company's market cap stands at $7.8 million. </li>
<li><strong>Springview Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares declined by 4.68% to $0.55. The market value of their outstanding shares is at $6.3 million. </li>
<li><strong>Volcon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares fell 3.61% to $0.76. The market value of their outstanding shares is at $2.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

FLYE

GORV

JDZG

LOBO

MTEN

NTCL

QVCGA

SPHL

VLCN

11 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 65.3% to $1.67 during Friday's after-market session. The market value of their outstanding shares is at $66.4 million. </li>
<li><strong>Tharimmune</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 9.35% to $1.67. The market value of their outstanding shares is at $3.2 million. </li>
<li><strong>CEL-SCI</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 7.45% to $0.27. The market value of their outstanding shares is at $22.6 million. </li>
<li><strong>BioCardia</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares moved upwards by 7.08% to $2.87. The market value of their outstanding shares is at $13.1 million. </li>
<li><strong>BioVie</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 6.66% to $1.28. The company's market cap stands at $23.6 million. </li>
<li><strong>LENZ Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock moved upwards by 6.63% to $31.48. The market value of their outstanding shares is at $867.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>TransCode Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 24.2% to $0.39 during Friday's after-market session. The company's market cap stands at $9.0 million. </li>
<li><strong>Impact BioMedical</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 15.75% to $0.63. The market value of their outstanding shares is at $7.2 million. </li>
<li><strong>Nexalin Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 12.09% to $1.6. The company's market cap stands at $21.2 million. </li>
<li><strong>BioLine Rx</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock declined by 10.86% to $3.04. The company's market cap stands at $11.3 million. </li>
<li><strong>Palisade Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 8.63% to $0.74. The market value of their outstanding shares is at $3.4 million. </li>
<li><strong>Plus Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 7.4% to $0.6. The company's market cap stands at $3.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BCDA

BIVI

BLRX

LENZ

PALI

PLRZ

PSTV

RNAZ

THAR

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>374Water</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock increased by 7.2% to $0.35 during Friday's after-market session. The company's market cap stands at $49.8 million. </li>
<li><strong>NeoVolta</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock increased by 5.26% to $3.6. The market value of their outstanding shares is at $120.2 million. </li>
<li><strong>Azul</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) stock moved upwards by 4.86% to $0.77. The market value of their outstanding shares is at $235.8 million. </li>
<li><strong>Stardust Power</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares rose 4.2% to $0.52. The market value of their outstanding shares is at $27.4 million. </li>
<li><strong>Aqua Metals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) stock rose 4.04% to $1.28. The market value of their outstanding shares is at $9.1 million. </li>
<li><strong>C3is</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) shares moved upwards by 3.82% to $4.07. The market value of their outstanding shares is at $2.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Click Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) stock decreased by 21.8% to $0.27 during Friday's after-market session. The market value of their outstanding shares is at $8.5 million. </li>
<li><strong>Freight Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) shares declined by 18.27% to $1.7. The company's market cap stands at $3.8 million. </li>
<li><strong>ManpowerGroup</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) shares declined by 9.68% to $39.97. The market value of their outstanding shares is at $1.8 billion. </li>
<li><strong>Singularity Future Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) shares declined by 5.63% to $0.88. The company's market cap stands at $3.6 million. </li>
<li><strong>JFB Construction</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>) shares declined by 5.56% to $4.25. The market value of their outstanding shares is at $39.3 million. </li>
<li><strong>CDT Environmental</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) stock decreased by 5.18% to $0.64. The company's market cap stands at $6.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AQMS

AZUL

CDTG

CISS

CLIK

FRGT

NEOV

SCWO

SDST

SGLY

12 Industrials Stocks Moving In Friday's After-Market Session

<p>Barclays  analyst Luke Sergott   maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and raises the price target from $55 to $75.</p>


Price Target

Analyst Ratings

EXAS

Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75

<h3>Gainers</h3>
<ul>
<li><strong>Marin Software</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares moved upwards by 15.0% to $0.65 during Friday's after-market session. The company's market cap stands at $2.0 million. </li>
<li><strong>SEMrush Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) shares moved upwards by 4.99% to $10.92. The company's market cap stands at $1.6 billion. </li>
<li><strong>Taoping</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) stock rose 4.86% to $0.23. The market value of their outstanding shares is at $3.0 million. </li>
<li><strong>PowerFleet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) shares increased by 4.85% to $5.4. The company's market cap stands at $715.5 million. </li>
<li><strong>Sigmatron Intl</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) stock moved upwards by 4.78% to $1.54. The company's market cap stands at $9.4 million. </li>
<li><strong>Brand Engagement Network</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock moved upwards by 3.98% to $0.34. The company's market cap stands at $14.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Greenidge Generation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock declined by 6.4% to $1.03 during Friday's after-market session. The company's market cap stands at $11.7 million. </li>
<li><strong>Gryphon Digital Mining</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares declined by 5.01% to $0.27. The market value of their outstanding shares is at $18.4 million. </li>
<li><strong>BIO-key Intl</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) shares decreased by 5.0% to $0.79. The market value of their outstanding shares is at $4.5 million. </li>
<li><strong>Rackspace Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) stock fell 4.97% to $1.34. The market value of their outstanding shares is at $317.9 million. </li>
<li><strong>Cemtrex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares decreased by 4.87% to $1.37. The company's market cap stands at $2.4 million. </li>
<li><strong>Locafy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) stock declined by 4.75% to $4.82. The market value of their outstanding shares is at $6.1 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AIOT

BKYI

BNAI

CETX

GREE

GRYP

LCFY

MRIN

SEMR

SGMA

TAOP

12 Information Technology Stocks Moving In Friday's After-Market Session

<p><strong>Alnylam Pharmaceuticals Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of $(1.03)</a>.</p>
<p>The company reported quarterly sales of $594.2 million, up 20% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45132168/alnylam-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights-recent-period-" rel="noreferrer noopener">consensus of $585.8 million</a>.</p>
<ul>
<li>Net product revenues increased 28% and 30% at actual currency and CER, respectively, due to growth from Amvuttra driven by increased patient demand, partially offset by a decrease in Onpattro due to patient switches to Amvuttra, and an increased number patients on Givlaari.</li>
<li><a href="https://www.benzinga.com/25/03/44463008/jp-morgan-sees-convincing-multi-billion-dollar-opportunity-for-alnylam-pharmaceuticals-upgrades-stock" target="_blank" rel="noreferrer noopener">Amvuttra</a> and Onpattro sales for the first quarter reached&nbsp;$310 million&nbsp;and&nbsp;$49 million, respectively, representing 36% growth compared to Q1 2024.</li>
<li>Givlaari and Oxlumo sales reached $67 million&nbsp;and&nbsp;$42 million, respectively, representing 8% growth.</li>
</ul>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a></strong></p>
<p><strong>Guidance: </strong>Alnylam affirmed fiscal 2025 sales guidance of $2.70 billion-$3 billion compared to the consensus of $2.91 billion, including:</p>
<ul>
<li>Total TTR net product revenues (Amvuttra and Onpattro) of $1.6 billion-$1.725 billion.</li>
<li>Total rare net product revenues (Givlaari and Oxlumo) of $450 million&nbsp;&#8211;&nbsp;$525 million.</li>
</ul>
<p>On Monday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Alnylam&#8217;s vutrisiran for wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). European Commission decision is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45036384/alnylam-receives-positive-chmp-opinion-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-c" rel="noreferrer noopener">expected in June 2025</a>.</p>
<p>&#8220;Commercially, we believe that the totality of the data leaves Amvuttra well positioned to achieve significant market share as 1st line therapy, and we are encouraged by the launch activities discussed on the conference call,&#8221; Chardan analyst Keay Nakae writes.</p>
<p>Nakae maintains the Buy rating with a<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings" target="_blank" rel="noreferrer noopener"> price target of $325</a>.</p>
<p>William Blair analyst Myles R. Minter writes, &#8220;On the ongoing Section 232 review of potential pharmaceutical tariffs, management highlighted minimal predicted exposure given that the majority of manufacturing processes and IP are housed within the U.S.&#8221;</p>
<p>Minter writes, &#8220;We continue to see Amvuttra as well positioned and differentiated in the lucrative TTR-CM market and would be buyers of Alnylam stock ahead of future quarters. Despite intraday volatility in trading, in part due to investor questions over why TTR-CM launch metrics like patient or script volume numbers were not provided when they are for<strong> BridgeBio Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby, we believe management remains confident about Amvuttra&#8217;s potential and early access/reimbursement metrics provided appear favorable for a product in the infancy of a launch.&#8221;</p>
<p><strong>Price Action:</strong> ALNY stock was up 1.67% at $259.39 on Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/media/25/05/45169853/taiwan-semiconductor-gains-on-strong-earnings-from-meta-and-microsoft-boosting-ai-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Gains On Strong Earnings From Meta And Microsoft Boosting AI Demand</a></strong></li>
</ul>
<p><em>Photo: Gorodenkoff/Shutterstock</em></p>


Analyst Color

Biotech

Large Cap

Guidance

Health Care

General

ALNY

BBIO

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

<p><strong>Paymentus Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Paymentus Holdings will report an <strong>earnings per share</strong> (EPS) of $0.13. </p>
<p>Investors in Paymentus Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 24.59% increase in the share price the following trading session.</p>
<p>Here's a look at Paymentus Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>0.09</td>
<td>0.09</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.13</td>
<td>0.15</td>
<td>0.12</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>25.0%</td>
<td>27.0%</td>
<td>14.000000000000002%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219814_0.png" alt="eps graph" /></p>
<h3>Market Performance of Paymentus Holdings's Stock</h3>
<p>Shares of Paymentus Holdings were trading at $33.45 as of May 01. Over the last 52-week period, shares are up 55.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Paymentus Holdings</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Paymentus Holdings.</p>
<p>Analysts have given Paymentus Holdings a total of 5 ratings, with the consensus rating being Outperform. The average one-year price target is $33.8, indicating a potential 1.05% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Euronet Worldwide, Remitly Global and WEX, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Euronet Worldwide, with an average 1-year price target of $118.0, suggesting a potential 252.77% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Remitly Global, with an average 1-year price target of $28.78, suggesting a potential 13.96% downside.</li>
<li>Analysts currently favor an Neutral trajectory for WEX, with an average 1-year price target of $162.14, suggesting a potential 384.72% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Euronet Worldwide, Remitly Global and WEX are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paymentus Holdings</td>
<td>Outperform</td>
<td>56.48%</td>
<td>$66.03M</td>
<td>2.76%</td>
</tr>
<tr>
<td>Euronet Worldwide</td>
<td>Neutral</td>
<td>-12.58%</td>
<td>$406.50M</td>
<td>3.04%</td>
</tr>
<tr>
<td>Remitly Global</td>
<td>Outperform</td>
<td>32.91%</td>
<td>$211.50M</td>
<td>-0.88%</td>
</tr>
<tr>
<td>WEX</td>
<td>Neutral</td>
<td>0.02%</td>
<td>$379M</td>
<td>6.22%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Paymentus Holdings ranks at the top for Revenue Growth and Gross Profit, outperforming its peers. However, it ranks at the bottom for Return on Equity. Overall, Paymentus Holdings is positioned favorably compared to its peers based on the provided metrics.</p>
<h3>Delving into Paymentus Holdings's Background</h3>
<p>Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.</p>
<h3>Paymentus Holdings: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Paymentus Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>56.48%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Paymentus Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>5.1%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Paymentus Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.76%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Paymentus Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.33%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<p><a href="https://www.benzinga.com/quote/PAY/earnings"><strong>To track all earnings releases for Paymentus Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Paymentus Holdings's Earnings Outlook

<p>Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Vornado Realty will report an <strong>earnings per share</strong> (EPS) of $0.52.</p>
<p>Anticipation surrounds Vornado Realty's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.10, which was followed by a 0.76% increase in the share price the next day.</p>
<p>Here's a look at Vornado Realty's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.51</td>
<td>0.55</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.61</td>
<td>0.52</td>
<td>0.57</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>13.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219806_0.png" alt="eps graph" /></p>
<h3>Tracking Vornado Realty's Stock Performance</h3>
<p>Shares of Vornado Realty were trading at $36.0 as of May 01. Over the last 52-week period, shares are up 39.84%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Vornado Realty</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Vornado Realty.</p>
<p>The consensus rating for Vornado Realty is Neutral, based on 5 analyst ratings. With an average one-year price target of $34.4, there's a potential 4.44% downside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of BXP, SL Green Realty and Kilroy Realty, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for BXP, with an average 1-year price target of $81.0, suggesting a potential 125.0% upside.</li>
<li>Analysts currently favor an Neutral trajectory for SL Green Realty, with an average 1-year price target of $64.5, suggesting a potential 79.17% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Kilroy Realty, with an average 1-year price target of $40.0, suggesting a potential 11.11% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for BXP, SL Green Realty and Kilroy Realty, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cousins Props</td>
<td>Outperform</td>
<td>14.39%</td>
<td>$152.38M</td>
<td>0.29%</td>
</tr>
<tr>
<td>BXP</td>
<td>Neutral</td>
<td>0.77%</td>
<td>$525.61M</td>
<td>1.14%</td>
</tr>
<tr>
<td>SL Green Realty</td>
<td>Neutral</td>
<td>-2.45%</td>
<td>$126.01M</td>
<td>-0.57%</td>
</tr>
<tr>
<td>Kilroy Realty</td>
<td>Neutral</td>
<td>6.45%</td>
<td>$194.10M</td>
<td>1.10%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Vornado Realty ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>About Vornado Realty</h3>
<p>Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.</p>
<h3>Key Indicators: Vornado Realty's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Vornado Realty displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>3.6%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Vornado Realty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>0.26%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vornado Realty's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.03%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vornado Realty's ROA excels beyond industry benchmarks, reaching <strong>0.01%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.26</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/VNO/earnings"><strong>To track all earnings releases for Vornado Realty visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Vornado Realty's Earnings Forecast

<p><strong>Titan America</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Titan America will report an <strong>earnings per share</strong> (EPS) of $0.20. </p>
<p>Investors in Titan America are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 0.75% drop in the share price the following trading session.</p>
<p>Here's a look at Titan America's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219797_0.png" alt="eps graph" /></p>
<h3>Performance of Titan America Shares</h3>
<p>Shares of Titan America were trading at $13.37 as of May 01. Over the last 52-week period, shares are down 20.18%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analysts' Perspectives on Titan America</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Titan America.</p>
<p>The consensus rating for Titan America is Buy, derived from 9 analyst ratings. An average one-year price target of $17.28 implies a potential 29.24% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Loma Negra Cia Industria, Knife River Holding and Eagle Materials, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Loma Negra Cia Industria, with an average 1-year price target of $14.0, suggesting a potential 4.71% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Knife River Holding, with an average 1-year price target of $111.0, suggesting a potential 730.22% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Eagle Materials, with an average 1-year price target of $254.25, suggesting a potential 1801.65% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Loma Negra Cia Industria, Knife River Holding and Eagle Materials are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titan America</td>
<td>Buy</td>
<td>-2.34%</td>
<td>$95.73M</td>
<td>4.83%</td>
</tr>
<tr>
<td>Loma Negra Cia Industria</td>
<td>Buy</td>
<td>-20.65%</td>
<td>$66.41B</td>
<td>4.27%</td>
</tr>
<tr>
<td>Knife River Holding</td>
<td>Outperform</td>
<td>1.60%</td>
<td>$114.11M</td>
<td>1.59%</td>
</tr>
<tr>
<td>Eagle Materials</td>
<td>Neutral</td>
<td>-0.14%</td>
<td>$177.81M</td>
<td>8.17%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Titan America is positioned in the middle among its peers for consensus rating. It ranks at the bottom for revenue growth. In terms of gross profit, it is at the top. For return on equity, it is positioned in the middle.</p>
<h3>Discovering Titan America: A Closer Look</h3>
<p>Titan America SA is a vertically integrated, multi-regional manufacturer and supplier of heavy building materials and services operating on the Eastern Seaboard. The Company, through its wholly owned subsidiaries, operates in the manufacture, distribution, and sale of cement, fly ash, aggregates, ready-mix concrete, and concrete blocks to resellers and construction contractors in the Eastern region of the United States.</p>
<h3>Titan America's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Titan America's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-2.34%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Titan America's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>9.37%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Titan America's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.83%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Titan America's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.35%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.61</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/TTAM/earnings"><strong>To track all earnings releases for Titan America visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TTAM

A Glimpse of Titan America's Earnings Potential

<p>Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is preparing to release its quarterly earnings on Monday, 2025-05-05. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Sabra Health Care REIT to report an <strong>earnings per share</strong> (EPS) of $0.36.</p>
<p>Investors in Sabra Health Care REIT are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.01, which was followed by a 0.97% drop in the share price the next day.</p>
<p>Here's a look at Sabra Health Care REIT's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.35</td>
<td>0.35</td>
<td>0.33</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.35</td>
<td>0.35</td>
<td>0.35</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219789_0.png" alt="eps graph" /></p>
<h3>Performance of Sabra Health Care REIT Shares</h3>
<p>Shares of Sabra Health Care REIT were trading at $17.62 as of May 01. Over the last 52-week period, shares are up 19.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Sabra Health Care REIT</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Sabra Health Care REIT.</p>
<p>A total of 2 analyst ratings have been received for Sabra Health Care REIT, with the consensus rating being Neutral. The average one-year price target stands at $19.0, suggesting a potential 7.83% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of National Health Investors, American Healthcare REIT and CareTrust REIT, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for National Health Investors, with an average 1-year price target of $82.0, suggesting a potential 365.38% upside.</li>
<li>Analysts currently favor an Outperform trajectory for American Healthcare REIT, with an average 1-year price target of $35.4, suggesting a potential 100.91% upside.</li>
<li>Analysts currently favor an Outperform trajectory for CareTrust REIT, with an average 1-year price target of $29.67, suggesting a potential 68.39% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for National Health Investors, American Healthcare REIT and CareTrust REIT, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabra Health Care REIT</td>
<td>Neutral</td>
<td>11.60%</td>
<td>$122.51M</td>
<td>1.70%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>Neutral</td>
<td>7.92%</td>
<td>$82.91M</td>
<td>3.33%</td>
</tr>
<tr>
<td>American Healthcare REIT</td>
<td>Outperform</td>
<td>12.47%</td>
<td>$112.17M</td>
<td>-1.42%</td>
</tr>
<tr>
<td>CareTrust REIT</td>
<td>Outperform</td>
<td>16.32%</td>
<td>$58.93M</td>
<td>1.95%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sabra Health Care REIT ranks in the middle for consensus rating. It ranks at the bottom for revenue growth. It is at the top for gross profit. It is at the bottom for return on equity.</p>
<h3>All You Need to Know About Sabra Health Care REIT</h3>
<p>Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.</p>
<h3>Sabra Health Care REIT's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Sabra Health Care REIT's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>11.6%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Sabra Health Care REIT's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>25.61%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sabra Health Care REIT's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.7%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Sabra Health Care REIT's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.88%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.89</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SBRA/earnings"><strong>To track all earnings releases for Sabra Health Care REIT visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SBRA

A Preview Of Sabra Health Care REIT's Earnings

<p><strong>Neurocrine Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Neurocrine Biosciences will report an <strong>earnings per share</strong> (EPS) of $1.25. </p>
<p>Investors in Neurocrine Biosciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 18.53% drop in the share price the following trading session.</p>
<p>Here's a look at Neurocrine Biosciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.71</td>
<td>1.51</td>
<td>1.03</td>
<td>1.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.69</td>
<td>1.81</td>
<td>1.63</td>
<td>1.20</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-19.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219781_0.png" alt="eps graph" /></p>
<h3>Neurocrine Biosciences Share Price Analysis</h3>
<p>Shares of Neurocrine Biosciences were trading at $106.59 as of May 01. Over the last 52-week period, shares are down 22.6%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Observations about Neurocrine Biosciences</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Neurocrine Biosciences.</p>
<p>The consensus rating for Neurocrine Biosciences is Buy, based on 18 analyst ratings. With an average one-year price target of $165.67, there's a potential 55.43% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Exelixis and Moderna, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Exelixis, with an average 1-year price target of $37.82, suggesting a potential 64.52% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Moderna, with an average 1-year price target of $40.22, suggesting a potential 62.27% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Exelixis and Moderna, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurocrine Biosciences</td>
<td>Buy</td>
<td>21.84%</td>
<td>$618.40M</td>
<td>3.88%</td>
</tr>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>18.16%</td>
<td>$546.79M</td>
<td>6.19%</td>
</tr>
<tr>
<td>Moderna</td>
<td>Neutral</td>
<td>-66.01%</td>
<td>$217M</td>
<td>-9.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Neurocrine Biosciences ranks highest in Revenue Growth and Gross Profit among its peers. However, it has the lowest Return on Equity. Overall, it is positioned in the top tier compared to its peers based on the provided metrics.</p>
<h3>Discovering Neurocrine Biosciences: A Closer Look</h3>
<p>Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.</p>
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Neurocrine Biosciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>21.84%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Neurocrine Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>16.43%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Neurocrine Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.88%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.84%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of <b>0.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/NBIX/earnings"><strong>To track all earnings releases for Neurocrine Biosciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NBIX

What to Expect from Neurocrine Biosciences's Earnings

<p>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Twist Bioscience will report an <strong>earnings per share</strong> (EPS) of $-0.57.</p>
<p>The announcement from Twist Bioscience is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.10, leading to a 1.38% drop in the share price the following trading session.</p>
<p>Here's a look at Twist Bioscience's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.63</td>
<td>-0.69</td>
<td>-0.77</td>
<td>-0.81</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.53</td>
<td>-0.59</td>
<td>-0.70</td>
<td>-0.79</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-19.0%</td>
<td>28.999999999999996%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219768_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Twist Bioscience were trading at $37.71 as of May 01. Over the last 52-week period, shares are down 12.16%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Twist Bioscience</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Twist Bioscience.</p>
<p>A total of 4 analyst ratings have been received for Twist Bioscience, with the consensus rating being Outperform. The average one-year price target stands at $50.25, suggesting a potential 33.25% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Veracyte, ACADIA Pharmaceuticals and Recursion Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Veracyte, with an average 1-year price target of $45.33, suggesting a potential 20.21% upside.</li>
<li>Analysts currently favor an Buy trajectory for ACADIA Pharmaceuticals, with an average 1-year price target of $25.0, suggesting a potential 33.7% downside.</li>
<li>Analysts currently favor an Buy trajectory for Recursion Pharmaceuticals, with an average 1-year price target of $9.0, suggesting a potential 76.13% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Veracyte, ACADIA Pharmaceuticals and Recursion Pharmaceuticals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twist Bioscience</td>
<td>Outperform</td>
<td>24.08%</td>
<td>$42.84M</td>
<td>-6.80%</td>
</tr>
<tr>
<td>Veracyte</td>
<td>Buy</td>
<td>20.81%</td>
<td>$78.75M</td>
<td>0.43%</td>
</tr>
<tr>
<td>ACADIA Pharmaceuticals</td>
<td>Buy</td>
<td>12.36%</td>
<td>$237.80M</td>
<td>21.95%</td>
</tr>
<tr>
<td>Recursion Pharmaceuticals</td>
<td>Buy</td>
<td>-57.54%</td>
<td>$-8.28M</td>
<td>-22.95%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Twist Bioscience ranks at the bottom for Revenue Growth and Gross Profit, while it is at the top for Return on Equity. Overall, Twist Bioscience's performance is mixed compared to its peers.</p>
<h3>Delving into Twist Bioscience's Background</h3>
<p>Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.</p>
<h3>Understanding the Numbers: Twist Bioscience's Finances</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Twist Bioscience showcased positive performance, achieving a revenue growth rate of <strong>24.08%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Twist Bioscience's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-35.61%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Twist Bioscience's ROE excels beyond industry benchmarks, reaching <strong>-6.8%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Twist Bioscience's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-5.17%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Twist Bioscience's debt-to-equity ratio is below the industry average at <strong>0.18</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/TWST/earnings"><strong>To track all earnings releases for Twist Bioscience visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TWST

What's Next: Twist Bioscience's Earnings Preview

<p>Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Freshpet to report an <strong>earnings per share</strong> (EPS) of $0.32.</p>
<p>Anticipation surrounds Freshpet's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.05 in the last quarter, leading to a 5.74% drop in the share price on the following day.</p>
<p>Here's a look at Freshpet's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.41</td>
<td>0.11</td>
<td>-0.03</td>
<td>-0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.24</td>
<td>-0.03</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>1.0%</td>
<td>5.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219759_0.png" alt="eps graph" /></p>
<h3>Performance of Freshpet Shares</h3>
<p>Shares of Freshpet were trading at $72.72 as of May 01. Over the last 52-week period, shares are down 36.91%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Freshpet</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Freshpet.</p>
<p>The consensus rating for Freshpet is Buy, derived from 17 analyst ratings. An average one-year price target of $126.29 implies a potential 73.67% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Flowers Foods, Simply Good Foods and Nomad Foods, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Flowers Foods, with an average 1-year price target of $20.5, suggesting a potential 71.81% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Simply Good Foods, with an average 1-year price target of $40.4, suggesting a potential 44.44% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Nomad Foods, with an average 1-year price target of $24.5, suggesting a potential 66.31% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Flowers Foods, Simply Good Foods and Nomad Foods, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freshpet</td>
<td>Buy</td>
<td>21.95%</td>
<td>$111.60M</td>
<td>1.75%</td>
</tr>
<tr>
<td>Flowers Foods</td>
<td>Neutral</td>
<td>-1.59%</td>
<td>$542.66M</td>
<td>3.06%</td>
</tr>
<tr>
<td>Simply Good Foods</td>
<td>Neutral</td>
<td>15.20%</td>
<td>$130.14M</td>
<td>2.04%</td>
</tr>
<tr>
<td>Nomad Foods</td>
<td>Outperform</td>
<td>4.29%</td>
<td>$225.90M</td>
<td>1.92%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Freshpet ranks highest in Revenue Growth among its peers, with a growth rate of 21.95%. In terms of Gross Profit, Freshpet is at the bottom with $111.60M. For Return on Equity, Freshpet is also at the bottom with a rate of 1.75%.</p>
<h3>Discovering Freshpet: A Closer Look</h3>
<p>Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.</p>
<h3>Freshpet: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Freshpet displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>21.95%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Freshpet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.9%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Freshpet's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.75%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Freshpet's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.4</strong>, Freshpet adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/FRPT/earnings"><strong>To track all earnings releases for Freshpet visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FRPT

An Overview of Freshpet's Earnings

<p>Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) is preparing to release its quarterly earnings on Monday, 2025-05-05. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Black Stone Minerals to report an <strong>earnings per share</strong> (EPS) of $0.34.</p>
<p>Anticipation surrounds Black Stone Minerals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.15, leading to a 1.14% increase in the share price the following trading session.</p>
<p>Here's a look at Black Stone Minerals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.33</td>
<td>0.35</td>
<td>0.36</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.18</td>
<td>0.41</td>
<td>0.29</td>
<td>0.27</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-0.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219751_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Black Stone Minerals were trading at $14.38 as of May 01. Over the last 52-week period, shares are down 12.93%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Opinions on Black Stone Minerals</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Black Stone Minerals.</p>
<p>The consensus rating for Black Stone Minerals is Neutral, derived from 2 analyst ratings. An average one-year price target of $15.5 implies a potential 7.79% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Gulfport Energy, Murphy Oil and California Resources, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Gulfport Energy, with an average 1-year price target of $216.67, suggesting a potential 1406.75% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Murphy Oil, with an average 1-year price target of $30.27, suggesting a potential 110.5% upside.</li>
<li>Analysts currently favor an Neutral trajectory for California Resources, with an average 1-year price target of $52.67, suggesting a potential 266.27% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Gulfport Energy, Murphy Oil and California Resources, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black Stone Minerals</td>
<td>Neutral</td>
<td>-23.52%</td>
<td>$80.38M</td>
<td>3.39%</td>
</tr>
<tr>
<td>Gulfport Energy</td>
<td>Buy</td>
<td>8.28%</td>
<td>$181.24M</td>
<td>-14.49%</td>
</tr>
<tr>
<td>Murphy Oil</td>
<td>Neutral</td>
<td>-20.50%</td>
<td>$180.58M</td>
<td>0.96%</td>
</tr>
<tr>
<td>California Resources</td>
<td>Neutral</td>
<td>55.03%</td>
<td>$1.34B</td>
<td>0.94%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Black Stone Minerals ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the top.</p>
<h3>Delving into Black Stone Minerals's Background</h3>
<p>Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.</p>
<h3>Black Stone Minerals's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Black Stone Minerals's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-23.52%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Black Stone Minerals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>37.37%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Black Stone Minerals's ROE excels beyond industry benchmarks, reaching <strong>3.39%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Black Stone Minerals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.21%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Black Stone Minerals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.02</strong>.</p>
<p><a href="https://www.benzinga.com/quote/BSM/earnings"><strong>To track all earnings releases for Black Stone Minerals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Black Stone Minerals's Upcoming Earnings

<p>Otter Tail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTTR#NASDAQ">OTTR</a>) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Otter Tail to report an <strong>earnings per share</strong> (EPS) of $1.53.</p>
<p>Otter Tail bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Otter Tail's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.28</td>
<td>1.98</td>
<td>1.69</td>
<td>1.45</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.30</td>
<td>2.03</td>
<td>2.07</td>
<td>1.77</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>4.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219741_0.png" alt="eps graph" /></p>
<h3>Tracking Otter Tail's Stock Performance</h3>
<p>Shares of Otter Tail were trading at $79.36 as of May 01. Over the last 52-week period, shares are down 10.63%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/OTTR/earnings"><strong>To track all earnings releases for Otter Tail visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


OTTR

Otter Tail's Earnings Outlook

<p>In the latest quarter, 11 analysts provided ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Glaukos, revealing an average target of $143.82, a high estimate of $200.00, and a low estimate of $86.00. A decline of 10.26% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219740_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Glaukos's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Glaukos's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Glaukos analyst ratings.</strong></a></p>
<h2>About Glaukos</h2>
<p>Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.</p>
<h3>Glaukos: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Glaukos's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.1%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-17.01%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Glaukos's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-2.37%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.87%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Glaukos's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.14</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GKOS

What 11 Analyst Ratings Have To Say About Glaukos

<p>CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that CRH will report an <strong>earnings per share</strong> (EPS) of $-0.09.</p>
<p>CRH bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 0.81% drop in the share price on the following day.</p>
<p>Here's a look at CRH's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.45</td>
<td>2.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.45</td>
<td>1.97</td>
<td>1.88</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>0.0%</td>
<td>1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>CRH Share Price Analysis</h3>
<p>Shares of CRH were trading at $96.28 as of May 01. Over the last 52-week period, shares are up 19.96%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CRH/earnings"><strong>To track all earnings releases for CRH visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


An Overview of CRH's Earnings

<p>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Vertex Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $4.31.</p>
<p>Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.04, which was followed by a 3.14% drop in the share price the next day.</p>
<p>Here's a look at Vertex Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>4.02</td>
<td>4.14</td>
<td>4.14</td>
<td>4.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.98</td>
<td>4.38</td>
<td>-12.83</td>
<td>4.76</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>6.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219725_0.png" alt="eps graph" /></p>
<h3>Vertex Pharmaceuticals Share Price Analysis</h3>
<p>Shares of Vertex Pharmaceuticals were trading at $498.86 as of May 01. Over the last 52-week period, shares are up 24.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Vertex Pharmaceuticals</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Vertex Pharmaceuticals.</p>
<p>The consensus rating for Vertex Pharmaceuticals is Neutral, derived from 12 analyst ratings. An average one-year price target of $473.92 implies a potential 5.0% downside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Gilead Sciences, Amgen and Regeneron Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Gilead Sciences, with an average 1-year price target of $118.81, suggesting a potential 76.18% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Amgen, with an average 1-year price target of $311.17, suggesting a potential 37.62% downside.</li>
<li>Analysts currently favor an Buy trajectory for Regeneron Pharmaceuticals, with an average 1-year price target of $790.94, suggesting a potential 58.55% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Gilead Sciences, Amgen and Regeneron Pharmaceuticals, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>Neutral</td>
<td>15.66%</td>
<td>$2.49B</td>
<td>5.70%</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Outperform</td>
<td>-11.92%</td>
<td>$5.99B</td>
<td>6.85%</td>
</tr>
<tr>
<td>Amgen</td>
<td>Neutral</td>
<td>10.86%</td>
<td>$5.97B</td>
<td>9.36%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Buy</td>
<td>-3.70%</td>
<td>$2.56B</td>
<td>2.75%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Vertex Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Discovering Vertex Pharmaceuticals: A Closer Look</h3>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<h3>Breaking Down Vertex Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>15.66%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Vertex Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>31.35%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vertex Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.7%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.08%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average at <strong>0.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/VRTX/earnings"><strong>To track all earnings releases for Vertex Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VRTX

Earnings Outlook For Vertex Pharmaceuticals

<p>6 analysts have expressed a variety of opinions on ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ITT and provided 12-month price targets. The average target is $156.17, accompanied by a high estimate of $168.00 and a low estimate of $148.00. A 5.64% drop is evident in the current average compared to the previous average price target of $165.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746219726_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of ITT among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$161.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Vladimir Bystricky</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$148.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$168.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ITT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ITT compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of ITT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ITT's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on ITT analyst ratings.</strong></a></p>
<h2>About ITT</h2>
<p>ITT began its journey as International Telephone &amp; Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.</p>
<h3>ITT's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> ITT's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>12.05%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> ITT's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>13.67%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> ITT's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.61%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> ITT's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.63%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> ITT's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.27</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying ITT: Insights From 6 Analyst Reviews

Press Releases

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Management

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

Allogene Therapeutics Announces Participation in February Investor Conferences

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Comments

Allogene Therapeutics

Vendite allo scoperto

Allogene Therapeutics (NASDAQ:ALLO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO